Advanced International Journal for Research

E-ISSN: 3048-7641   •   Impact Factor: 9.11

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6, Issue 6 (November-December 2025) Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 6
November-December 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Regenerating Hope in India : Stem Cell Innovations for Premature Ovarian Insufficiency

Author(s) Dr. NIHARIKA SHARMA
Country India
Abstract Background: Premature ovarian insufficiency (POI)—loss of ovarian activity before age 40 with oligo/amenorrhea, elevated FSH, and low estradiol—affects ~1–4% of women <40 and ~1 in 1,000 under 30 globally. In India, multiple analyses of NFHS/LASI datasets suggest notable burdens of premature/early menopause with rural and socioeconomic gradients, magnifying cardiometabolic and psychosocial risks. As patients and clinics increasingly seek “ovarian rejuvenation,” stem cell–based strategies (mesenchymal stem cells [MSCs], menstrual blood–derived cells, amniotic/umbilical sources, cell-free exosomes) and adjacent biologics (platelet-rich plasma, PRP) have entered the conversation—often ahead of robust evidence. Indian law is clear that any clinical use of stem cells (beyond approved HSCT indications) must occur only within regulated clinical trials. (PubMed)
Objective: To synthesize global scientific progress on stem cell innovations for POI and translate it to Indian realities—clinical, social, regulatory, and financing—so that clinicians, policymakers, researchers, and affected communities can make informed, ethical decisions.
Methods: Targeted narrative review (2020–2025 prioritized) of peer-reviewed studies, systematic reviews/meta-analyses, registered trials, Indian and international guidelines (ESHRE/ASRM/IMS; ICMR/DBT; CDSCO/NDCTR; ART Act/Rules), plus credible educational podcasts/webinars and media/press releases. We triangulated biological/technical evidence with India-specific policies and health-system data. (ESHRE)
Key findings:
1. Promise with caveats: Preclinical and early clinical signals suggest MSCs and cell-free exosomes can improve ovarian function markers in POI, yet high-quality human evidence remains limited; safety, durability, and live-birth impact are unsettled. (PMC)
2. India’s regulatory line is bright: NGSCR 2017 and ICMR’s evidence compendium state clinical stem cell use is experimental (outside HSCT) and must be in approved trials only. Commercial “rejuvenation” outside trials is unethical. (Department of Biotechnology)
3. Care gaps: Costly IVF, limited public fertility services, and uneven counseling in local languages drive out-of-pocket (OOP) medicalization and vulnerability to unproven offerings. (HTAIn)
4. Roadmap: India can lead ethically by: (a) multicenter POI-stem cell registries; (b) GMP-grade trials (menstrual/amnion/umbilical MSCs or exosomes) with patient-centric, multilingual consent; (c) coverage pilots following HTAIn costing; and (d) national communication campaigns to counter misinformation. (HTAIn)
Keywords Premature ovarian insufficiency (POI), Mesenchymal stem cells (MSCs), Exosomes, Ovarian rejuvenation, Platelet-rich plasma (PRP), Regulation (ICMR/DBT, NGSCR 2017, ART Act 2021), Clinical trials, In-vitro activation (IVA), Fertility preservation, Hormone therapy (HT
Field Medical / Pharmacy
Published In Volume 6, Issue 5, September-October 2025
Published On 2025-10-04
DOI https://doi.org/10.63363/aijfr.2025.v06i05.1474
Short DOI https://doi.org/g96fxq
View / Download PDF File

Share this



E-ISSN 3048-7641
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About AIJFR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-79-39-59 editor@aijfr.com